12:00 AM
 | 
May 28, 2012
 |  BC Week In Review  |  Company News  |  Deals

Kinex Pharmaceuticals, Xiangxue deal

Kinex granted Xiangxue exclusive rights in China, Taiwan and Singapore to develop and commercialize KX02 for cancer. KX02 is a lipophilic dual inhibitor of...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >